Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
about
Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV InfectionAn update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet countsPeripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.Thrombocytopenia and bleeding in veterans with non-hepatitis C-related chronic liver disease.Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries.Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.Monoclonal antibody Rituximab for severe immune thrombocytopenia after pegylated interferon for hepatitis C infection.Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.Thrombocytopenia in chronic liver disease.Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection.Management algorithm for genotype 1 hepatitis C virus.Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future.Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.Hepatitis C: management of side effects in the era of direct-acting antivirals.Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions.Correcting thrombocytopenia in patients with liver diseases: a difficult hurdle.
P2860
Q24200189-3396B739-9A48-4156-896F-C425544A8DEDQ28606732-B7AA4EDD-8B02-43B3-920E-5E440DE09163Q30453975-4CD57884-503F-4AEF-83BA-5CF89C6C57B9Q33399240-9E0895BB-904D-420D-A2E7-3BCDF6E609C2Q33400529-AE8D902D-5EFB-4186-81DC-D899EC44F9D5Q33403528-7E7E7966-075A-40D7-ABEB-20082FE85A43Q33414281-BBBD3E70-78A6-4DBC-A1D7-6E32A17AC6D2Q33414392-0DA7B4A6-6E80-4872-B124-9A5742552B09Q33421239-839CF72A-FD36-4FE5-B4B2-22D07E403043Q33423471-BDAD200F-9D0F-4923-8510-7CB1609E6F7BQ33423922-05DCA143-2CE0-4329-8E84-54EAA5209D1FQ33424397-A280961E-083C-4761-A98A-FD6FE8C5FE4BQ33430833-E86EF19D-9FFC-4435-83D5-7B375704FF27Q33436905-4219AD0D-0DF8-4A69-8E09-8DADD46F807AQ35082620-2E8BB5E2-1634-4C0C-A0DB-E24D9492288DQ36984871-06C790D2-0695-42B2-9A6C-7FD235F85B1EQ37846232-B73E5B77-F5F5-4FE3-BE3D-2AF485BD3FAEQ37851006-3F28C4AD-1FA5-4B6E-A8A3-30F4AC7E0A58Q38069957-93A0BDC0-E95A-4290-8AF9-1DAA9B87A1F7Q40878925-9A1E35BE-3895-41B8-8324-929D095CAD87Q42245471-63D2454D-B50F-43A5-B1C5-C84227450B75Q45749628-C285B260-19C7-4677-8FFB-10C1F6BA9DDE
P2860
Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Thrombocytopenia and the risk ...... virin for chronic hepatitis C.
@ast
Thrombocytopenia and the risk ...... virin for chronic hepatitis C.
@en
type
label
Thrombocytopenia and the risk ...... virin for chronic hepatitis C.
@ast
Thrombocytopenia and the risk ...... virin for chronic hepatitis C.
@en
prefLabel
Thrombocytopenia and the risk ...... virin for chronic hepatitis C.
@ast
Thrombocytopenia and the risk ...... virin for chronic hepatitis C.
@en
P2093
P1476
Thrombocytopenia and the risk ...... virin for chronic hepatitis C.
@en
P2093
Harry L A Janssen
Robert J de Knegt
Robert Roomer
P304
P356
10.1016/J.JHEP.2010.04.013
P50
P577
2010-06-01T00:00:00Z